158 related articles for article (PubMed ID: 20409340)
21. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.
Manuri PR; Nehete B; Nehete PN; Reisenauer R; Wardell S; Courtney AN; Gambhira R; Lomada D; Chopra AK; Sastry KJ
Vaccine; 2007 Apr; 25(17):3302-10. PubMed ID: 17291642
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs.
Bousarghin L; Touze A; Gaud G; Iochmann S; Alvarez E; Reverdiau P; Gaitan J; Jourdan ML; Sizaret PY; Coursaget PL
Mol Cancer Ther; 2009 Feb; 8(2):357-65. PubMed ID: 19174559
[TBL] [Abstract][Full Text] [Related]
23. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ
Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722
[TBL] [Abstract][Full Text] [Related]
24. High-Risk Alphapapillomavirus Oncogenes Impair the Homologous Recombination Pathway.
Wallace NA; Khanal S; Robinson KL; Wendel SO; Messer JJ; Galloway DA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768872
[TBL] [Abstract][Full Text] [Related]
25. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
Li YL; Qiu XH; Shen C; Liu JN; Zhang J
Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
[TBL] [Abstract][Full Text] [Related]
26. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
27. Immunoexpression of HPV 16/18 E6 and E7 oncoproteins in high-grade cervical squamous intraepithelial lesions in HIV-positive women.
Rodrigues LC; Speck NM; Focchi GR; Schimidt MA; Marques RM; Ribalta JC
Genet Mol Res; 2016 Feb; 15(1):. PubMed ID: 26909984
[TBL] [Abstract][Full Text] [Related]
28. HPV16 oncogenes E6 or/and E7 may influence the methylation status of RASSFIA gene promoter region in cervical cancer cell line HT-3.
Yin F; Wang N; Wang S; Yu F; Sun X; Yu X; Luo B; Zhao C; Wang Y
Oncol Rep; 2017 Apr; 37(4):2324-2334. PubMed ID: 28260046
[TBL] [Abstract][Full Text] [Related]
29. DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection.
Chandra J; Dutton JL; Li B; Woo WP; Xu Y; Tolley LK; Yong M; Wells JW; R Leggatt G; Finlayson N; Frazer IH
J Immunother; 2017; 40(2):62-70. PubMed ID: 28166181
[TBL] [Abstract][Full Text] [Related]
30. Distribution of human papilloma virus type 16 E6/E7 gene mutation in cervical precancer or cancer: A case control study in Guizhou Province, China.
Yang Y; Ren J; Zhang Q
J Med Virol; 2016 Feb; 88(2):345-50. PubMed ID: 26192265
[TBL] [Abstract][Full Text] [Related]
31. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
[TBL] [Abstract][Full Text] [Related]
32. Combination Vaccination With Tetanus Toxoid and Enhanced Tumor-Cell Based Vaccine Against Cervical Cancer in a Mouse Model.
Alson D; Schuyler SC; Yan BX; Samimuthu K; Qiu JT
Front Immunol; 2020; 11():927. PubMed ID: 32547541
[TBL] [Abstract][Full Text] [Related]
33. Eradication of cervical cancer in vivo by an AAV vector that encodes shRNA targeting human papillomavirus type 16 E6/E7.
Sato N; Saga Y; Uchibori R; Tsukahara T; Urabe M; Kume A; Fujiwara H; Suzuki M; Ozawa K; Mizukami H
Int J Oncol; 2018 Mar; 52(3):687-696. PubMed ID: 29344635
[TBL] [Abstract][Full Text] [Related]
34. Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.
Morishima S; Akatsuka Y; Nawa A; Kondo E; Kiyono T; Torikai H; Nakanishi T; Ito Y; Tsujimura K; Iwata K; Ito K; Kodera Y; Morishima Y; Kuzushima K; Takahashi T
Int J Cancer; 2007 Feb; 120(3):594-604. PubMed ID: 17096336
[TBL] [Abstract][Full Text] [Related]
35. Transcriptional gene silencing of HPV16 E6/E7 induces growth inhibition via apoptosis in vitro and in vivo.
Zhou J; Peng C; Li B; Wang F; Zhou C; Hong D; Ye F; Cheng X; Lü W; Xie X
Gynecol Oncol; 2012 Feb; 124(2):296-302. PubMed ID: 22056554
[TBL] [Abstract][Full Text] [Related]
36. [Experimental studies of using real-time fluorescence quantitative PCR and RT-PCR to detect E6 and E7 genes of human papillomavirus type 16 in cervical carcinoma cell lines].
Chen YY; Peng ZL; Liu SL; He B; Hu M
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jun; 38(3):443-6. PubMed ID: 17593827
[TBL] [Abstract][Full Text] [Related]
37. In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma.
Madrigal M; Janicek MF; Sevin BU; Perras J; Estape R; Peñalver M; Averette HE
Gynecol Oncol; 1997 Jan; 64(1):18-25. PubMed ID: 8995542
[TBL] [Abstract][Full Text] [Related]
38. Assessment of human papillomavirus E6/E7 oncogene expression as cervical disease biomarker.
Fontecha N; Basaras M; Hernáez S; Andía D; Cisterna R
BMC Cancer; 2016 Nov; 16(1):852. PubMed ID: 27816058
[TBL] [Abstract][Full Text] [Related]
39. [Construction and identification of non-replication recombinant vaccinia virus co-expressing human papillomavirus type 16 L1/L2/E6/E7 proteins].
Huang W; Tian HW; Ren J; Fan JT; Zhao L; Bian T; Lu ZH; Ruan L
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Sep; 19(3):240-3. PubMed ID: 16261206
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of DNA vaccines forming e7 recombinant retroviral virus-like particles for the treatment of human papillomavirus-induced cancers.
Lescaille G; Pitoiset F; Macedo R; Baillou C; Huret C; Klatzmann D; Tartour E; Lemoine FM; Bellier B
Hum Gene Ther; 2013 May; 24(5):533-44. PubMed ID: 23521528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
